Controlled clinical trial with pirfenidone in the treatment of breast capsular contracture: Association of TGF-β polymorphisms

Annals of Plastic Surgery

Volumn 70, Issue 1, 2013, Pages 16-22

  Veras Castillo, Evelin Rosaira ^a   Cardenas Camarena, Lazaro ^a   Lyra Gonzalez, Ivan ^b   Muñoz Valle, Jose Francisco ^b   Lucano Landeros, Silvia ^b   Guerrerosantos, Jose ^a   Gonzalez Ulloa, Beatriz ^c   Mercado Barajas, Jose Luis ^b   Sanchez Parada, Maria Guadalupe ^b   Azabache Wennceslao, Ronney ^a   Armendariz Borunda, Juan ^b,d  

^a Instituto Jalisciense de Cirugía Reconstructiva Dr José Guerrerosantos   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c Diagnóstico Especializado Por Imagen DEI ^*  (Mexico)

^d HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

antifibrotic therapy; Baker Score; breast capsular contracture; pirfenodone; TGF beta polymorphysms

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BREAST AUGMENTATION; BREAST IMPLANT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; ECHOGRAPHY; EQUIPMENT; FEMALE; FOLLOW UP; GENETIC MARKER; GENETICS; HOMOZYGOTE; HUMAN; IMPLANT CAPSULAR CONTRACTURE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PILOT STUDY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST IMPLANTATION; BREAST IMPLANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HOMOZYGOTE; HUMANS; IMPLANT CAPSULAR CONTRACTURE; MIDDLE AGED; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84871618456     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31822284f4     Document Type: Article

References (44)

1. Rowland JH, Desmond KA, Meyerowitz BE, et al. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst. 2000;92: 1422-1429.
2. rd Consensus Conference, Regensburg, Germany, 1998.
3. Ersek RA. Rate and incidence of capsular contracture: a comparison of smooth and textured silicone double-lumen breast prostheses. Plast Reconstr Surg. 1991;87: 879-884.
4. Barnsley GP, Sigurdson LJ, Barnsley SE. Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2006; 117: 2182-2190.
5. Siggelkow W, Faridi A, Spiritus K, et al. Histological analysis of silicone breast implant capsules and correlation with capsular contracture. Biomaterials. 2003;24: 1101-1109.
6. Dolores W, Rainer C, Niederegger H, et al. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions. J Autoimmunity. 2004;23: 81-91.
7. Ulrich D, Lichtenegger F, Eblenkamp M, et al. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants. Plast Reconstr Surg. 2004; 114: 229-236.
8. Wyatt LE, Sinow JD, Wollman JS, et al. The influence of time on human breast capsule histology: smooth and textured silicone-surfaced implants. Plast Reconstr Surg. 1998;102: 1922-1931.
9. Loosing C, Hanson HA. Peptide growth factor and myofibroblast in capsules around human breast implants. Plast Reconstr Surg. 1993;91: 1277-1286.
10. Vistnes LM, Ksander GA, Isaacs G, et al. Elevated glycosaminoglycans and chondroitin 4-sulfate and other properties of contracted human prosthesis capsules. Ann Plast Surg. 1981;7: 195-203.
11. Prantl L, Schreml S, Fichtner-Feigl S, et al. Clinical and morphological conditions in capsular contracture formed around silicone breast implants. Plast Reconstr Surg. 2007;120: 275-284.
12. Gabriel SE, Woods JE, O'Fallon WM, et al. Complications leading to surgery after breast implantation. N Engl J Med. 1997;336: 677-682.
13. Kuhn A, Singh S, Smith PD, et al. Periprosthetic breast capsules contain the fibrogenic cytokines TGF-A1 and TGF-A2, suggesting possible new treatment approaches. Ann Plast Surg. 2000;44: 387-391.
14. Brohim RM, Foresman PA, Hildebrandt PK, et al. Early tissue reaction to textured breast implant surfaces. Ann Plast Surg. 1992;28: 354-362.
15. Schreml S, Heine N, Eisenmann-Klein M, et al. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mam-maplasty. Ann Plast Surg. 2007;59: 126-130.
16. Burkhardt BR, Dempsey PD, Schnur PL, et al. Capsular contracture: a prospective study of the effect of local antibacterial agents. Plast Reconstr Surg. 1986;77: 919-932.
17. Caffee HH. Intracapsular injection of triamcinolone for intractable capsule contracture. Plast Reconstr Surg. 1994;94: 824-828.
18. Lemperle G, Exner K. Effect of cortisone on capsular contracture in double-lumen breast implants: ten years' experience. Aesthetic Plast Surg. 1993; 17: 317-323.
19. Vazquez B, Given KS, Houston GC. Breast augmentation: a review of sub-glandular and submuscular implantation. Aesthetic Plast Surg. 1987;11: 101-105.
20. Chang L, Caldwell E, Reading G, et al. A comparison of conventional and low-bleed implants in augmentation mammaplasty. Plast Reconstr Surg. 1992; 89: 79-82.
21. Van Heerden J, Turner M, Hoffmann D, et al. Antimicrobial coating agents: can biofilm formation on a breast implant be prevented? J Plast Reconstr Aesthet Surg. 2009;62: 610-617.
22. Gutowski KA, Mesna GT, Cunninghan BL. Saline-filled breast implants: a Plastic Surgery Educational Foundation multicenter outcomes study. Plast Reconstr Surg. 1997;100: 1019-1024.
23. Spear SL, Elmaraghy M, Hess C. Textured-surface saline-filled silicone breast implants for augmentation mammaplasty. Plast Reconstr Surg. 2000; 105: 1542-1552.
24. Tamboto H, Vickery K, Deva AK. Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammaplasty. Plast Reconstr Surg. 2010;126: 835-842.
25. Zimman OA, Toblli J, Stella I, et al. The effects of angiotensin- converting-enzyme inhibitors on the fibrous envelope around mammary implants. Plast Reconstr Surg. 2007;120: 2025-2030.
26. Adams WP Jr, Haydon MS, Raniere J Jr, et al. A rabbit model for capsular contracture: development and clinical implications. Plast Reconstr Surg. 2006;117: 1214-1219.
27. Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;1: 3-16.
28. Gancedo M, Ruiz-Corro L, Salazar-Montes A, et al. Pirfenidone in capsular contracture after mammary implantation. Aesthetic Plast Surg. 2008;32: 32-40.
29. Armendariz-Borunda J, Rincon AR, Muñoz-Valle JF, et al. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J Investig Med. 2008;56: 944-953.
30. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31: 828-833.
31. Tag CG, Mengsteab S, Hellerbrand C, et al. Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by light cycle analysis in patients with chronic hepatitis C infection. Cytokine. 2003;24: 173-181.
32. Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-beta 1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168: 431-435.
33. Bayat A, Bock O, Mrowietz U, et al. Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels. Plast Reconstr Surg. 2003;111: 535-543.
34. Zahavi A, Sklair ML, Ad-El DD. Capsular contracture of the breast: working towards a better classification using clinical and radiologic assessment. Ann Plast Surg. 2006;57: 248-251.
35. Baker JL Jr. Augmentation Mammaplasty: Symposium on Aesthetic Surgery of the Breast. St Louis, MO: C. V. Mosley Company; 1978;256-263.
36. Wood NA, Thomson SC, Smith RM, Bidwell JL. Identification of human TGF-A1 signal (leader) sequence polymorphisms by PCR-RFLP. J Immunol Methods. 2000;234(1-2): 117-122.
37. Oliver J, Agundez JA, Morales S, et al. Polymosrphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease. Liver Int. 2005;25: 935-939.
38. Wang H, Mengsteab S, Tag CG, et al. Transforming growth factor-beta 1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005;11: 1929-1936.
39. D'Andrea F, Nicoletti GF, Grella E, et al. Modification of cysteinyl leuko-triene receptor expression in capsular contracture. Ann Plast Surg. 2007;58: 212-214.
40. Huang CK, Handel N. Effects of Singulair (montelukast) treatment for capsular contracture. Aesthet Surg J. 2010;30:404-408.
41. Stump A, Holton LH III, Connor J, et al. The use of acellular dermal matrix to prevent capsule formation around implants in a primate model. Plast Reconstr Surg. 2009;124: 82-91.
42. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2006;55: 1663-1665.
43. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary Fibrosis. Am J Respir Crit Care Med. 2005;171: 1040-1047.
44. Brazova J, Sismova K, Vavrova V, et al. Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin Immunol. 2006;121: 350-357.